Immunome to Present at 2024 Bank of America Healthcare Conference
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, and radioligand therapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Has Signed a ?37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium ? July 3, 2024, 12:30pm CET / 6:30am ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)...
The report "Anti-Migrating Agent Market by Type (Non-ionic, Anionic, Cationic, Amphoteric), Grades (Technical, Food, Pharmaceutical), Application, Chemistry (Organic, Inorganic), End-Use Industry (Textile, Plastics, Paper), and Region - Global...
Gupshup, the world's leading Conversation Cloud, in collaboration with Meta, the Sudan Medical Specialization Board and non-profit Shabaka today announced the launch of a telemedicine chatbot providing healthcare access for Sudanese refugees in...
The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...
The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...
Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...
